Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26925497 | 1.00 | BCHE (0.41) | BCHEMAOBPDK1 | |
| SCHEMBL21070445 | 0.87 | BCHE (0.40) | BCHEMAOBPDK1 | |
| SCHEMBL21070814 | 0.87 | BCHE (0.40) | BCHEMAOBPDK1 | |
| SCHEMBL21070687 | 0.83 | BCHE (0.39) | BCHEMAOBPDK1 | |
| SCHEMBL21069432 | 0.83 | BCHE (0.39) | BCHEMAOBPDK1 | |
| SCHEMBL21071408 | 0.83 | BCHE (0.39) | BCHEMAOBPDK1 | |
| SCHEMBL25997678 | 0.80 | BCHE (0.31) | BCHE | |
| SCHEMBL26923076 | 0.80 | PDK1 (0.32) | BCHEPDK1 | |
| SCHEMBL28515788 | 0.75 | KDM4E (0.36) | BCHEMAOB | |
| SCHEMBL26280385 | 0.75 | CHRM2 (0.40) | PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BCHE 2634/4885MAOB 2743/4885PDK1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.